KR910006287A - 비페닐메탄 유도체 및 약리학적 이용 - Google Patents

비페닐메탄 유도체 및 약리학적 이용 Download PDF

Info

Publication number
KR910006287A
KR910006287A KR1019900015702A KR900015702A KR910006287A KR 910006287 A KR910006287 A KR 910006287A KR 1019900015702 A KR1019900015702 A KR 1019900015702A KR 900015702 A KR900015702 A KR 900015702A KR 910006287 A KR910006287 A KR 910006287A
Authority
KR
South Korea
Prior art keywords
methyl
imidazo
pyridine
tetrazol
biphenyl
Prior art date
Application number
KR1019900015702A
Other languages
English (en)
Other versions
KR930000168B1 (ko
Inventor
가즈도시 미야께
마사유끼 마쓰꾸라
나오끼 요네다
오사무 히로시마
노부유끼 모오리
히로끼 이시하라
다까시 무샤
도시유끼 마쓰오까
사찌유끼 하마노
노리오 미나미
Original Assignee
나이또오 하루오
에자이 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나이또오 하루오, 에자이 가부시끼가이샤 filed Critical 나이또오 하루오
Publication of KR910006287A publication Critical patent/KR910006287A/ko
Application granted granted Critical
Publication of KR930000168B1 publication Critical patent/KR930000168B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

비페닐메탄 유도체 및 약리학적 이용
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 다음 식(Ⅰ) :
    의 비페닐메탄유도체 또는 약리학적으로 허용되는 그의 염.
    식중, R1은 수소, 알킬, 시클로알킬, 할로겐화알킬, -S-R7, -SO2-R7, -C≡C-R7또는 -(CH2)p-OR7이고, R7은 수소, 알킬, 시클로알킬 또는 할로겐화알킬이고, p는 0 또는 1 이고, -A1=A2-A3=A4-는 -CH=CH-CH=CH-, -N=CH-CH=C-H-, CH=N-CH=CH-, -CH=CH-N=CH-, -CH=CH-CH=N- 또는 -CH=N-CH=N-이고, R2와 R3는 각각 수소, 할로겐, 저급 알킬, 저급 알콕시, 카르바모일 또는 시아노이고, R4는 수소 또는 저급 알킬이고, R5는 1H-테트라졸-5-일, 카르복실(-COOH) 또는 카르복실 에스테르이고 R6은 수소, 할로겐, 히드록실 또는 저급 알콕시이다.
  2. 제1항에 있어서, R5가 카르복실인 것을 특징으로하는 비페닐메탄 유도체 또는 약리학적으로 허용되는 그의 염.
  3. 제1항에 있어서, R5가 1H-테트라졸-5-일인것을 특징으로 하는 비페닐메탄 유도체 또는 약리학적으로 허용되는 그의 염.
  4. 제1항에 있어서, R5가 탄소수 1내지 6인 알킬이 있는 카르복실에스테르인 것을 특징으로 하는 비페닐메탄 유도체 또는 약리학적으로 허용되는 그의 염.
  5. 제1항에 있어서, R1이 메틸, 에틸, 프로필, 메톡시, 에톡시 및 시클로프로필로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 비페닐메탄 유도체 또는 약리학적으로 허용되는 그의 염.
  6. 제1항에 있어서, -A1=A2-A3=A4-가 -CH=CH-CH=N-인 것을 특징으로 하는 비페닐메탄 유도체 또는 약리학적으로 허용되는 그의 염.
  7. 제1항에 있어서, R2가 A1상의 수소이고 R3가 A3상의 메틸: R2가 A1상의 메틸이고 R3가 A3상의 메틸이거나: R2가 A1상의 메틸이고 R3가 A3상의 수소인것을 특징으로하는 비페닐메탄 유도체 또는 약리학적으로 허용되는 그의 염.
  8. 제1항에 있어서, R4가 수소이고 R6가 수소인것을 특징으로하는 비페닐메탄 유도체 또는 약리학적으로 허용되는 그의 염.
  9. 제1항에 있어서, 7-메틸-2-n-프로필-3-〔(2'-(1H-테트라졸-5-일)-비페닐-4-일-메틸〕-3H-이미다조〔4ㅡ5-b〕피리딘 또는 3-〔(2'-카르복실비페닐-4-일)메틸〕-2-시클로프로필-7-메틸-3H-이미다조〔4,5-b〕피리딘인것을 특징으로하는 비페닐메탄 유도체 또는 약리학적으로 허용되는 그의 염.
  10. 제1항에 있어서, 하기 화합물중의 하나인것을 특징으로 하는 비페닐 메탄유도체 또는 약리학적으로 허용되는 그의 염.
    2-에틸-7-메틸-3[{2'-(1H-테트라졸-5-일)비페닐-4-일}메틸]-3H-이미다조[4,5-b]피리딘,3-{(2'-카르복시비페닐-4-일)메틸}-7-메틸-2-n-프로필-3H-이미다조[4,5-b]피리딘, 2-시클로프로필-7-메틸-3-[{2'-)1H-테트라졸-5-일)비페닐-4-일}메틸]-3H-이미다조[4,5-b]피리딘, 3-[{5'-클로로-2'(1H-테트라졸-5-일)비페닐-4-일}메틸]-7-메틸-2-n-프로필-3H-이미다조[4,5-b]피리딘, 3-{(2'-카르복시비페닐-4-일)메틸}-2-에틸티오-7-메틸-3H-이미다조[4,5-b]피리딘, 3-{(2'카르복시-5'-클로로비페닐-4-일)메틸}-2-시클로프로필-7-메틸-3H-이미다조[4,5-b]피리딘, 2-n-프로필-3-[{2'-(1H-테트라졸-5-일)비페닐-4-일}메틸]-3H-이미다조[4,5-b]피리딘, 2-시클로프로필-5,7-디메틸-3-[{2'-(1H-테트라졸-5-일)비페닐-4-일}메틸]-3H-이미다조[4,5-b]피리딘, 3-{(2'-카르복시비페닐-4-일)메틸}-2-시클로프로필-5,7-디메틸-3H-이미다조[4,5-b]피리딘, 5,7-디메틸-2-n-프로필-3[{2'-(1H-테트라졸-5-일)비페닐-4-일}메틸]-3H=이미다조[4,5-b]피리딘, 3-{(2'-카르복시비페닐-4-일)메틸}-2-n-프로필-5,7-디메틸-3H-이미다조[4,5-b]피리딘, 2-에톡시-7-메틸-3-[{2'-(1H-테트라졸-5-일)비페닐-4-일}-3H-이미다조[4,5-b]피리딘, 7-메틸-2-n-프로폭시-3-[{2'-(1H-테트라졸-5-일)비페닐-4-일}메틸]-3H-이미다조[4,5-b]피리딘, 7-메틸-2-(1-프로피닐)-3-[{2'-(1H-테트라졸-5-일)비페닐-4-일}메틸]-3H-이미다조[4,5-b]피리딘, 2-에틸티오-7-메틸-3-[{2'-(1H-테트라졸-5-일)비페닐-4-일}메틸]-3H-이미다조[4,5-b] 피리딘, 3-{2'-카르복시비페닐-4-일)메틸}-2-에틸-7-메틸-3H-이미다조[4,5-b]피리딘, 2-에톡시-5,7-디메틸-3[{2'-(1H-테트라졸-5-일)비페닐-4-일}메틸]-3H-이미다조[4,5-b]피리딘, 5,7-디메틸-2-메톡시-3-[{2'-(1H-테트라졸-5-일)비페닐-4-일}메틸]-3H-이미다조[4,5-b]피리딘, 5,7-디메틸-2-n-프로폭시-3-[{2'-(1H-테트라졸-5-일)비페닐-4-일}메틸]-3H-이미다조[4,5-b]피리딘, 3-{2'-카르복시비페닐-4-일)메틸}-2-에톡시-7-메틸-3H-이미다조[4,5-b]피리딘, 3-{(2'-카르복시비페닐-4-일)메틸}-2-메톡시-7-메틸-3H-이미다조[4,5,-b]피리딘, 3-{(2'카르복시비페닐-4-일)메틸}-7-메틸-2-n-프로폭시-3H-이미다조[4,5-b]피리딘, 3-{2'-카르복시비페닐-4-일)메틸}-5,7-디메틸-2-에톡시-3H-이미다조[4,5-b]피리딘, 3-{2'-카르복시비페닐-4-일)메틸}-5,7-디메틸-2-메톡시-3H-이미다조[4,5-b]피리딘, 3-{2'-카르복시비페닐-4-일)메틸}-5,7-디메틸-2-프로폭시-3H-이미다조[4,5-b]피리딘.
  11. 약리학적으로 효과적인 양의 제1항에서 정의한 비페닐메탄 유도체 또는 약리학적으로 허용되는 그의 염 및 약리학적으로 허용되는 담체로 이루어지는 것을 특징으로 하는 약리학적 조성물.
  12. 약리학적으로 효과적인 양의 제1항에서 정의한 비페닐메탄 유도체 또는 약리학적으로 허용되는 그의 염을 환자에게 투여함으로써 고혈압증을 예방 및 치료하는 방법.
  13. 약리학적으로 효과적인 양의 제1항에서 정의한 비페닐메탄 유도체 또는 약리학적으로 허용되는 그의 염을 환자에게 투여함으로써 심기능 부전을 예방 및 치료하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900015702A 1989-09-29 1990-09-29 비페닐메탄 유도체 화합물 KR930000168B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP25176189 1989-09-29
JP251761 1989-09-29
JP1-251761 1989-09-29
JP33664089 1989-12-27
JP1-336640 1989-12-27
JP336640 1989-12-27

Publications (2)

Publication Number Publication Date
KR910006287A true KR910006287A (ko) 1991-04-29
KR930000168B1 KR930000168B1 (ko) 1993-01-11

Family

ID=26540341

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900015702A KR930000168B1 (ko) 1989-09-29 1990-09-29 비페닐메탄 유도체 화합물

Country Status (21)

Country Link
US (1) US5328911A (ko)
EP (3) EP0420237B1 (ko)
JP (2) JP2608341B2 (ko)
KR (1) KR930000168B1 (ko)
CN (1) CN1025331C (ko)
AT (3) ATE152451T1 (ko)
AU (1) AU641685B2 (ko)
CA (1) CA2026533A1 (ko)
DD (1) DD299301A5 (ko)
DE (3) DE69025687T2 (ko)
DK (1) DK0420237T3 (ko)
ES (1) ES2085876T3 (ko)
FI (1) FI94527C (ko)
GR (1) GR3019239T3 (ko)
HU (1) HUT55367A (ko)
IE (1) IE70593B1 (ko)
MX (1) MXPA95000470A (ko)
NO (1) NO176912C (ko)
NZ (1) NZ235469A (ko)
PT (1) PT95464B (ko)
RU (1) RU2024521C1 (ko)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0273071A (ja) * 1988-09-09 1990-03-13 Sumitomo Chem Co Ltd ベンズイミダゾール誘導体、その製造法およびそれを有効成分とする殺虫、殺ダニ剤
IE64514B1 (en) * 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
US5223499A (en) * 1989-05-30 1993-06-29 Merck & Co., Inc. 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
US5332744A (en) * 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
IL95975A (en) * 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5250554A (en) * 1989-10-24 1993-10-05 Takeda Chemical Industries, Ltd. Benzimidazole derivatives useful as angiotensin II inhibitors
EP0443983B1 (de) * 1990-02-19 1996-02-28 Ciba-Geigy Ag Acylverbindungen
DE4006693A1 (de) * 1990-03-01 1991-09-05 Schering Ag Neue benzimidazolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5703110A (en) * 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US6004989A (en) 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5194379A (en) * 1990-05-11 1993-03-16 Merck & Co., Inc. Microbial transformation process for the preparation of hydroxylanol imidazo (4,5-b) pyridines useful as angiotensin II receptor antagonists
DE69130192T2 (de) * 1990-06-08 1999-03-25 Hoechst Marion Roussel Inc Benzimidazol-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, ihre Anwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen
FR2674523A1 (fr) * 1991-03-28 1992-10-02 Roussel Uclaf Nouveaux derives de benzimidazole, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
FR2670489B1 (fr) * 1990-12-18 1994-10-14 Roussel Uclaf Nouveaux derives de benzimidazole, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
DE4023215A1 (de) * 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
DE4023369A1 (de) * 1990-07-23 1992-01-30 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
RU1836357C (ru) * 1990-07-23 1993-08-23 Др.Карл Томэ ГмбХ Производные бензимидазола, их изомеры, смеси изомеров, гидраты или их физиологически переносимые соли, обладающие антагонистическими в отношении ангиотензина свойствами
EP0470543A1 (de) * 1990-08-10 1992-02-12 Dr. Karl Thomae GmbH Heterocyclische Imidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zur ihrer Herstellung
US5210206A (en) * 1990-09-10 1993-05-11 Abbott Laboratories 1,3-oxazolyl substituted biphenyl
AU636066B2 (en) * 1990-10-30 1993-04-08 Takeda Chemical Industries Ltd. Thienoimidazole derivatives, their production and use
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
TW274551B (ko) * 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
MX9202300A (es) * 1991-05-16 1992-11-01 Glaxo Group Ltd Derivados de benzofurano, procedimiento para su preparacion y composicion farmaceutica que los contiene.
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
SG42942A1 (en) * 1991-09-10 1997-10-17 Tanabe Seiyaku Co Imidazopyridine derivatives and process for preparation thereof
TW300219B (ko) * 1991-09-14 1997-03-11 Hoechst Ag
TW284688B (ko) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
GB9201715D0 (en) * 1992-01-28 1992-03-11 Ici Plc Chemical process
DE4219534A1 (de) * 1992-02-19 1993-12-16 Thomae Gmbh Dr K Substituierte Biphenylylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5208234A (en) * 1992-03-10 1993-05-04 E. R. Squibb & Sons, Inc. Substituted imidazole phosphonic and phosphinic acid derivatives
EP0602246A4 (en) * 1992-03-25 1995-07-05 Green Cross Corp ISOINDAZOLE COMPOUND.
DE4305602A1 (de) * 1992-06-17 1993-12-23 Merck Patent Gmbh Imidazopyridine
CA2139930A1 (en) * 1992-07-10 1994-01-20 Alan Martin Birch Dioxycyclobutene derivatives as angiotensin ii antagonists
AU675660B2 (en) * 1992-07-17 1997-02-13 Merck & Co., Inc. Substituted biphenylmethylimidazopyridines
EP0627433B1 (en) * 1992-12-07 2003-03-05 Eisai Co., Ltd. Process for producing imidazopyridine derivative and intermediate
RU2109736C1 (ru) * 1992-12-17 1998-04-27 Санкио Компани Лимитед Производные бифенила и способ их получения
DE4320432A1 (de) * 1993-06-21 1994-12-22 Bayer Ag Substituierte Mono- und Bipyridylmethylderivate
US5338740A (en) * 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
KR0151816B1 (ko) * 1994-02-08 1998-10-15 강박광 신규의 치환된 피리딜 이미다졸 유도체 및 그의 제조방법
US5753672A (en) * 1994-04-19 1998-05-19 Tanabe Seiyaku Co., Ltd. Imidazopyridine derivatives and process for preparing the same
US6110923A (en) * 1994-06-22 2000-08-29 Biochem Pharma Inc. Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
ATE225173T1 (de) * 1995-08-02 2002-10-15 Univ Newcastle Ventures Ltd Benzimidazol verbindungen
US6071931A (en) * 1995-10-06 2000-06-06 Novartis Ag AT1 -receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
TW526202B (en) * 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
NZ587909A (en) 1998-12-23 2012-05-25 Novartis Ag Process of making a compressed tablets containing valsartan and microcrystalline cellulose
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
AU2003242984A1 (en) * 2003-04-07 2004-11-01 Hetero Drugs Limited A novel crystalline form of irbesartan
EA011281B1 (ru) 2004-12-21 2009-02-27 Пфайзер Продактс Инк. Макролиды
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
WO2008096829A1 (ja) 2007-02-07 2008-08-14 Kyowa Hakko Kirin Co., Ltd. ３環系化合物
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
KR101009383B1 (ko) 2008-04-30 2011-01-19 켐젠주식회사 고순도의2-부틸-3-[[2'-(1에이취-테트라졸-5-일)[1,1'-비페닐]-4-일]메틸]-1,3-디아자스피로[4.4]논-1-엔-4-온 화합물의제조방법
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR20130076046A (ko) * 2011-12-28 2013-07-08 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
EA202090205A1 (ru) 2017-07-07 2020-06-02 Бёрингер Ингельхайм Ветмедика Гмбх Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4870186A (en) * 1987-05-22 1989-09-26 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4874867A (en) * 1987-05-22 1989-10-17 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US4916129A (en) * 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
DE3928177A1 (de) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2016710A1 (en) * 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IE64514B1 (en) * 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
EP0415886A3 (en) * 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
IL95975A (en) * 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
IL96019A0 (en) * 1989-10-31 1991-07-18 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
EP0434038A1 (en) * 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
CA2041763A1 (en) * 1990-05-11 1991-11-12 Sheih-Shung T. Chen Microbial transformation process for antihypertensive products
JPH04235974A (ja) * 1990-06-08 1992-08-25 Roussel Uclaf 新規なイミダゾール誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物
DE69130192T2 (de) * 1990-06-08 1999-03-25 Hoechst Marion Roussel Inc Benzimidazol-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, ihre Anwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen
CA2044806A1 (en) * 1990-07-18 1992-01-19 Roland Jaunin Purine derivatives
RU1836357C (ru) * 1990-07-23 1993-08-23 Др.Карл Томэ ГмбХ Производные бензимидазола, их изомеры, смеси изомеров, гидраты или их физиологически переносимые соли, обладающие антагонистическими в отношении ангиотензина свойствами
EP0470543A1 (de) * 1990-08-10 1992-02-12 Dr. Karl Thomae GmbH Heterocyclische Imidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zur ihrer Herstellung

Also Published As

Publication number Publication date
FI94527B (fi) 1995-06-15
EP0420237A1 (en) 1991-04-03
DE69032414T2 (de) 1998-11-19
DE69025687T2 (de) 1996-08-08
DE69030631D1 (de) 1997-06-05
DE69030631T2 (de) 1997-09-25
ES2085876T3 (es) 1996-06-16
EP0628557A1 (en) 1994-12-14
PT95464B (pt) 1997-07-31
JPH03236377A (ja) 1991-10-22
CA2026533A1 (en) 1991-03-30
JPH07224059A (ja) 1995-08-22
ATE152451T1 (de) 1997-05-15
GR3019239T3 (en) 1996-06-30
NO904202L (no) 1991-04-02
AU6307590A (en) 1991-04-11
NO176912B (no) 1995-03-13
ATE167186T1 (de) 1998-06-15
DE69032414D1 (de) 1998-07-16
KR930000168B1 (ko) 1993-01-11
FI94527C (fi) 1995-09-25
EP0628557B1 (en) 1997-05-02
EP0420237B1 (en) 1996-03-06
IE70593B1 (en) 1996-12-11
DE69025687D1 (de) 1996-04-11
ATE134998T1 (de) 1996-03-15
FI904424A0 (fi) 1990-09-07
NO176912C (no) 1995-06-21
JP2925962B2 (ja) 1999-07-28
EP0598702A1 (en) 1994-05-25
JP2608341B2 (ja) 1997-05-07
NZ235469A (en) 1993-03-26
CN1025331C (zh) 1994-07-06
NO904202D0 (no) 1990-09-27
US5328911A (en) 1994-07-12
AU641685B2 (en) 1993-09-30
RU2024521C1 (ru) 1994-12-15
CN1050539A (zh) 1991-04-10
DD299301A5 (de) 1992-04-09
DK0420237T3 (da) 1996-07-01
HU906243D0 (en) 1991-03-28
PT95464A (pt) 1991-05-22
MXPA95000470A (es) 2004-08-17
HUT55367A (en) 1991-05-28
IE903242A1 (en) 1991-04-10
EP0598702B1 (en) 1998-06-10

Similar Documents

Publication Publication Date Title
KR910006287A (ko) 비페닐메탄 유도체 및 약리학적 이용
JP2001525411A5 (ko)
KR940014396A (ko) 이미다조피리딘
DE3375785D1 (en) Benzodiazepine receptors and their preparation
CO5080744A1 (es) Ligandos de alta afinidad para el receptor de nociceptina orl-1
KR920006347A (ko) 헤테로사이클릭 유도체
KR950018006A (ko) 이미다조피리딘
KR910000737A (ko) 악액질(cachexia)의 치료방법 및 이 방법에 사용되는 화합물
ZA81977B (en) Substituted imidazole derivatives and their preparation and use
KR890016020A (ko) 융합 피리미딘, 그의 제조 및 용도
PE20030664A1 (es) DERIVADOS DE TRIAZOLO [4,3-a]PIRIDO[2,3-d]PIRIMIDIN-5-ONA, COMPOSICIONES QUE LOS CONTIENEN, METODO DE PREPARACION Y USO
NO156048C (no) Analogifremgangsmaate for fremstilling av farmasoeytisk aktive imidazopyridinderivater
RU96111027A (ru) Трициклические 5,6-дигидро-9h-пиразоло [3,4-c]-1,2,4-триазоло [4,3-a]пиридины
JPH09506339A (ja) α▲下２▼アドレナリン作動剤としての２−（２−アルキルフェニルアミノ）−オキサゾリン、−チアゾリンおよび−イミダゾリンの用途
IE56121B1 (en) Tricyclic and tetracyclic imidazo(1,5-a)(1,4)benzodiazepine-1-carboxylate derivatives
KR890017252A (ko) 티에노트리아졸로디아제핀 화합물 및 그의 약학적 용도
AR004691A1 (es) Nuevos derivados de [3-alcoxi-fenoxi-)-etil]-dialquilamina, una composicion farmaceutica que los comprende, su uso como anestesicos locales y unprocedimiento para su preparacion
ES538933A0 (es) Un procedimiento para preparar imidazo(1,2-c)pirimidinas
ATE29721T1 (de) 5-(4-vinyl- oder 4-ethynylbenzoyl)-1,2-dihydro-3h-pyrrolo-(1,2-a -pyrrol-1-carbosaeure und deren derivate.
KR880005134A (ko) 인돌로-피라지노-벤조 디아제민 유도체
MX7118E (es) Procedimiento para preparar derivados de imidazol(1,2-a)quinoleina
ES557324A0 (es) Un procedimiento para preparar nuevas imidazo(1,2-a)pirimidinas'
KR880009037A (ko) 14,15-치환된 라노스테롤 및 그의 콜레스테롤 저하제로서의 용도
ES8705413A1 (es) Un procedimiento para preparar derivados de benzopirano.
JPS57175193A (en) Preparation of triazolopyrimidine derivative

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19971222

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee